Hormone therapy and Alzheimer's disease: Benefit or harm?

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 389-406

  Henderson, Victor W ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Alzheimer's disease; Cognition; Dementia; Hormone therapy; Menopause; Oestrogen; Progestin; Women's health

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PIPERAZINE ESTRONE SULFATE; PRESENILIN 1; PRESENILIN 2;

AGE; AGED; ALZHEIMER DISEASE; BRAIN BLOOD VESSEL; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; ENZYME INHIBITION; FEMALE; GENE LOCATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; OVARIECTOMY; POSTMENOPAUSE; RECEPTOR DOWN REGULATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 1242341933     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.389     Document Type: Review

References (243)

1. TRÉVOUX R, DE BRUX J, CASTANIER M, NAHOUL K, SOULE J-P, SCHOLLER R: Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas (1986) 8:309-326.
2. MCKINLAY SM, BRAMBILLA DJ, POSNER JG: The normal menopause transition. Maturitas (1992) 14:103-115.
3. BURGER HG, DUDLEY EC, HOOPER JL et al.: Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J. Clin. Endocrinol. Metab. (1999) 84:4025-4030.
4. JUDD HL, FOURNET N: Changes of ovarian hormonal function with aging. Exp. Gerontol. (1994) 29:285-298.
5. TONG S, WALLACE EM, BURGER HG: Inhibins and activins: clinical advances in reproductive medicine. Clin. Endocrinol, (Oxf) (2003) 58:115-127.
6. BURGER HG, DUDLEY EC, CUI J, DENNERSTEIN L, HOPPER JL: A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J. Clin. Endocrinol. Metab. (2000) 85:2832-2838.
7. LAUNER LJ, ANDERSEN K, DEWEY ME et al.: Rates and risk factors for dementia and Alzheimeis disease: results from EURODEM pooled analyses. Neurology (1999) 52:78-84.
8. KUKULL WA, HIGDON R, BOWEN JD et al.: Dementia and Alzheimer's disease incidence: a prospective cohort study. Arch. Neurol. (2002) 59:1737-1746.
9. KNOPMAN DS, PARISI JE, BOEVE BF et al.: Vascular dementia in a population-based autopsy study. Arch. Neurol (2003) 60:569-575.
10. JORM AF, KORTEN AE, HENDERSON AS: The prevalence of dementia: a quantitative integration of the literature. Acta Pychiatr. Scand. (1987) 76:465-479.
11. GAO S, HENDRIE HC, HALL KS, HUI S: The relationships between age, sex, and incidence of dementia and Alzheimer's disease: a meta-analysis. Arch. Gen. Psychiatry (1998) 55:809-815.
12. KEMPER TL: Neuroanatomical and neuropathological changes during aging and dementia. In: Clinical Neurology of Aging (2nd edn). Albert ML, Knoefel JE (Eds), Oxford University Press, New York (1994):3-67.
13. GOEDERT M, WISCHIK CM, CROWTHER RA, WALKER JE, KLUG A: Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer's disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA (1988) 85:4051-4055.
14. GOATE A, CHARTIER-HARLIN M-C, MULLAN M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349:704-706.
15. SHERRINGTON R, ROGAEV EI, LIANG Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375:754-760.
16. LEVY-LAHAD, E, WIJSMAN EM, NEMENS E et al.: A familial Alzheimer's disease locus on chromosome 1. Science (1995) 269:970-973.
17. HONG M, TROJANOWSKI JQ, LEE VM-Y: Tau-based neurofibrillary lesions. In: Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms. Trojanowski JQ (Ed.), McGraw-Hill, New York (2000):161-175.
18. GÖTZ J, CHEN F, VAN DORPE J, NITSCH RM: Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A42 fibrils. Science (2001) 293:1491-1495.
19. POIRIER J: Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. (2003) 9:94-101.
20. NÄSLUND J, THYBERG J, TJERNBERG LO et al.: Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron (1995) 15:219-228.
21. GYLYS KH, FEIN JA, TAN AM, COLE GM: Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J. Neurochem. (2003) 84:1442-1451.
22. POLVIKOSKI T, SULKAVA R, HALTIA M et al.: Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N. Engl. J. Med. (1995) 333:1242-1247.
23. SELKOE DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. (2001) 81:741-746.
24. FARRER LA, CUPPLES LA, HAINES JL et al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. JAMA (1997) 278:1349-1356.
25. BRETSKY PM, BUCKWALTER JG, SEEMAN TE et al.: Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer's disease. Alzheimer. Dis. Assoc. Disord. (1999) 13:216-221.
26. STONE DJ, ROZOVSKY I, MORGAN TE, ANDERSON CP, HAJIAN H, FINCH CE: Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. (1997) 143:313-318.
27. KATZMAN R: Education and the prevalence of dementia and Alzheimer's disease. Neurology (1993) 43:13-20.
28. MORTIMER JA, FRENCH LR, HUTTON JT, SCHUMAN LM: Head injury as a risk factor for Alzheimer's disease. Neurology (1985) 35:264-267.
29. SKOOG I, LERNFELT B, LANDAHL S et al.: 15-year longitudinal study of blood pressure and dementia. Lancet (1996) 347:1141-1145.
30. KIVIPELTO M, HELKALA EL, LAAKSO MP et al.: Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Br. Med. J. (2001) 322:1447-1451.
31. SESHADRI S, BEISER A, SELHUB J et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. (2002) 346:476-483.
32. IN T'VELD BA, RUITENBERG A, HOFMAN A et al.: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med (2001) 345:1515-1521.
33. WOLOZIN B, KELLMAN W, RUOSSEAU P, CELESIA GG, SIEGEL G: Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. (2000) 57:1439-1443.
34. MUKAMAL KJ, KULLER LH, FITZPATRICK AL, LONGSTRETH WT Jr, MITTLEMAN MA, SISCOVICK DS: Prospective study of alcohol consumption and risk of dementia in older adults. JAMA (2003) 289:1405-1413.
35. WILSON RS, MENDES DE LEON CF, BARNES LL et al.: Participation in cognitively stimulating activities and risk of incident Alzheimer's disease. JAMA (2002) 287:742-748.
36. LAURIN D, VERREAULT R, LINDSAY J, MACPHERSON K, ROCKWOOD K: Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch. Neurol. (2001) 58:498-504.
37. SHUMAKER SA, LEGAULT C, RAPP SR et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study (WHIMS). JAMA (2003) 289:2651-2662.
38. GRONEMEYER H: Control of transcription activation by steroid hormone receptors. FASEB J. (1992) 6:2524-2529.
39. SHUGHRUE PJ, LANE MV, MERCHENTHALER I: Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J. Comp. Neurol. (1997) 388:507-525.
40. SHUGHRUE PJ, SCRIMO PJ, MERCHENTHALER I: Evidence for the colocalization of estrogen receptor-beta mRNA and estrogen receptor-alpha immunoreactivity in neurons of the rat forebrain. Endocrinology (1998) 139:5267-5270.
41. SHUGHRUE PJ, MERCHENTHALER I: Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system. J. Comp. Neurol. (2001) 436:64-81.
42. KUIPER GGJM, CARLSSON B, GRANDIEN K et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology (1997) 138:863-870.
43. FALKENSTEIN E, NORMAN AW, WEHLING M: Mannheim classification of nongenomically initiated (rapid) steroid action(s). J. Clin. Endocrinol. Metab. (2000) 85:2072-2075.
44. WONG M, THOMPSON TL, MOSS RL: Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms. Crit. Rev. Neurobiol. (1996) 10:189-203.
45. LEVIN ER: Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol. Metab. (1999) 10:374-377.
46. MOOSMANN B, BEHL C: The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc. Natl. Acad. Sci. USA (1999) 96:8867-8872.
47. DYKENS JA, SIMPKINS JW, WANG J, GORDON K: Polycyclic phenots, estrogens and neuroprotection: a proposed mitochondrial mechanism. Exp. Gerontol. (2003) 38:101-107.
48. SANTAGATI S, MELCANGI RC, CELOTTI F, MARTINI L, MAGGI A: Estrogen receptor is expressed in different types of glial cells in culture. J. Neurochem. (1994) 63:2058-2064.
49. SHI J, SIMPKINS JW: 17β-estradiol modulation of glucose transporter 1 expression in blood-brain barrier. Am. J. Physiol. (1997) 272:E1016-E1022.
50. NAMBA H, SOKOLOFF L: Acute administration of high doses of estrogen increases glucose utilization throughout brain. Brain Res. (1984) 291:391-394.
51. OHKURA T, TESHIMA Y, ISSE K et al.: Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause (1995) 2:13-18.
52. COYLE JT, PRICE DL, DELONG MR: Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (1983) 219:1184-1190.
53. RASOOL CG, SVENDSEN CN, SELKOE DJ: Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer's disease. Ann. Neurol. (1986) 20:482-488.
54. BONDAREFF W, MOUNTJOY CQ, ROTH M et al.: Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer's disease. Alzheimer Dis. Assoc. Disord. (1987) 1:256-262.
55. YAMAMOTO T, HIRANO A: Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann. Neurol. (1985) 17:573-577.
56. SHUGHRUE PJ, SCRIMO PJ, MERCHENTHALER I: Estrogen binding and estrogen receptor characterization (ERα and ERβ) in the cholinergic neurons of the rat basal forebrain. Neuroscience (2000) 96:41-49.
57. LUINE V: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp. Neurol. (1985) 89:484-490.
58. GABOR R, NAGLE R, JOHNSON DA, GIBBS RB: Estrogen enhances potassium-stimulated acetylcholine release in the rat hippocampus. Brain Res. (2003) 962:244-247.
59. WU X, GLINN MA, OSTROWSKI NL et al.: Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. (1999) 847:98-104.
60. BETHEA CL, LU NZ, GUNDLAH C, STREICHER JM: Diverse actions of ovarian steroids in the serotonin neural system. Front. Neuroendocrinol. (2002) 23:41-100.
61. HERBISON AE, SIMONIAN SX, THANKY NR, BICKNELL RJ: Oestrogen modulation of noradrenaline neurotransmission. Novartis Found. Symp. (2000) 230:74-85.
62. HENDERSON VW. Hormone Therapy and the Brain: A Clinical Perspective an the Role of Estrogen. Parthenon Publishing, New York (2000).
63. SMITH MA, PERRY G, RICHEY PL et al.: Oxidative damage in Alzheimer's. Nature (1996) 382:120-121.
64. GOODMAN Y, BRUCE AJ, CHENG B, MATTSON MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J. Neurochem. (1996) 66:1836-1844.
65. BEHL C, SKUTELLA T, LEZOUALCH F et al.: Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharmacol. (1997) 51:535-541.
66. WANG J, GREEN PS, SIMPKINS JW: Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J. Neurochem. (2001) 77:804-811.
67. REGAN RF, GUO Y. Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain Res. (1997) 764:133-140.
68. GARCIA-SEGURA LM, CARDONA-GOMEZ P, NAFTOLIN F, CHOWEN JA: Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport (1998) 9:593-597.
69. L expression and β-amyloid-induced apoptosis: relevance to Alzheimer's disease. J. Neurochem. (1999) 72:1552-1563.
70. TORAN-ALLERAND CD, MIRANDA RC, BENTHAM WDL et al.: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA (1992) 89:4668-4672.
71. SOHRABJI F, MIRANDA RCG, TORAN-ALLERAND CD: Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. USA (1995) 92:11110-11114.
72. TORAN-ALLERAND CD: Organotypic culture of the developing cerebral cortex and hypothalamus: relevance to sexual differentiation. Psychoneuroendocrinology (1991) 16:7-24.
73. BRINTON RD, TRAN J, PROFFITT P, MONTOYA M: 17 β-estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem. Res. (1997) 22:1339-1351.
74. WOOLLEY CS, MCEWEN BS: Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J. Comp. Neurol. (1993) 336:293-306.
75. SCHEIBEL ME, LINDSAY RD, TOMIYASU U, SCHEIBEL AN: Progressive dendritic changes in aging human cortex. Exp. Neurol, (1975) 47:392-403.
76. MASLIAH E, MALLORY M, ALFORD M et al.: Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 56:127-129.
77. ESTUS S, TUCKER HM, VAN ROOYEN C et al.: Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant 'apoptotic' pattern of gene induction. J. Neurosci. (1997) 17:7736-7745.
78. ROGERS J, COOPER NR, WEBSTER S et al.: Complement activation by beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1992) 89:10016-10020.
79. SMALL DH, NURCOMBE V, REED G et al.: A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. (1994) 14:2117-2127.
80. MORIMOTO T, OHSAWA I, TAKAMURA C, ISHIGURO M, KOHSAKA S: Involvement of amyloid precursor protein in functional synapse formation in cultured hippocampal neurons. J. Neurosci. Res. (1998) 51:185-195.
81. LORENZO A, YANKNER BA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA (1994) 91:12243-12247.
82. BEHL C, LEZOUALC'H F, TRAPP T, WIDMANN M, SKUTELLA T, HOLSBOER F: Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology (1997) 138:101-106.
83. HONJO H, KIKUCHI N, HOSODA T et al.: Alzheimer's disease and estrogen. J. Steroid Biochem. Mol. Biol. (2001) 76:227-230.
84. 1-40-induced toxicity in septal-derived cholinergic SN56 cells. J. Neurochem. (2003) 85:1180-1189.
85. SAGARA Y, DARGUSCH R, KLIER FG, SCHUBERT D, BEHL C: Increased antioxidant enzyme activity in amyloid β protein-resistant cells. J. Neurosci. (1996) 16:497-505.
86. JAFFE AB, TORAN-ALLERAND CD, GREENGARD P, GANDY SE: Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. J. Biol. Chem. (1994) 269:13065-13068.
87. SEUBERT P, VIGO-PELFREY C, ESCH F et al.: Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 359:268-269.
88. XU H, GOURAS GK, GREENFIELD JP et al.: Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat. Med. (1998) 4:447-451.
89. ZHENG H, XU H, ULJON SN et al.: Modulation of Aβ peptides by estrogen in mouse models. J. Neurochem. (2002) 80:191-196.
90. PETANCESKA SS, NAGY G, FRAIL D, GANDY S: Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Neurology (2000) 54:2212-2217.
91. GREENFIELD JP, LEUNG LW, CAI D et al.: Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis. J. Biol. Chem. (2002) 277:12128-12136.
92. KOJRO E, GIMPL G, LAMMICH S, MARZ W, FAHRENHOLZ F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. USA (2001) 98:5815-5820.
93. REFOLO LM, PAPPOLLA MA, LAFRANCOIS J et al: A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. (2001) 8:890-899.
94. WRITING GROUP FOR THE PEPI TRIAL: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA (1995) 273:199-208.
95. SCHLEGEL W, PETERSDORF LI, JUNKER R, SCHULTE H, EBERT C, VON ECKARDSTEIN A: The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women. Clin. Endocrinol. (Oxf) (1999) 51:643-651.
96. LOBO RA, BUSH T, CARR BR, PICKAR JH: Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil. Steril. (2001) 76:13-24.
97. NEUROINFLAMMATION WORKING GROUP: Inflammation and Alzheimer's disease. Neurobiol. Aging (2000) 21:383-421.
98. SHEN Y, SULLIVAN T, LEE CM, MERI S, SHIOSAKI K, LIN CW. Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide. Brain Res. (1998) 796:187-197.
99. TCHELINGERIAN JL, VIGNAIS L, JACQUE C: TNF alpha gene expression is induced in neurones after a hippocampal lesion. Neuroreport (1994) 5:585-588.
100. SUZUKI S, TANAKA K, NAGATA E, ITO D, DEMBO T, FUKUUCHI Y: Cerebral neurons express interleukin-6 after transient forebrain ischemia in gerbils. Neurosci. Lett. (1999) 262:117-120.
101. GABAY C, KUSHNER I: Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. (1999) 340:448-454.
102. PRADHAN AD, MANSON JE, ROSSOUW JE et al.: Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA (2002) 288:980-987.
103. ROST NS, WOLF PA, KASE CS et al.: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke (2001) 32:2575-2579.
104. CAO JJ, THACH C, MANOLIO TA et al.: C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation (2003) 108:166-170.
105. WASSERTHEIL-SMOLLER S, HENDRIX S, LIMACHER M et al.: Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 289:2673-2684.
106. SCHMIDT R, SCHMIDT H, CURB JD, MASAKI K, WHITE LR, LAUNER LJ: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. (2002) 52:168-174.
107. YASOJIMA K, SCHWAB C, MCGEER EG, MCGEER PL: Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. (2000) 887:80-89.
108. MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47:425-432.
109. LIM GP, YANG F, CHU T et al.: Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. (2000) 20:5709-5714.
110. GROSSMAN CJ: Interactions between the gonadal steroids and the immune system. Science (1985) 227:257-261.
111. THOMAS T, BRYANT M, CLARK L, GARCES A, RHODIN J: Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction. Microvasc. Res. (2001) 61:28-39.
112. CANTATORE FP, LOVERRO G, INGROSSO AM et al.: Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin. Rheumatol. (1995) 14:157-160.
113. LUYER MD, KHOSLA S, OWEN WG, MILLER VM: Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J. Clin. Endocrinol. Metab. (2001) 86:3629-3634.
114. BERG G, EKERFELT C, HAMMAR M, LINDGREN R, MATTHIESEN L, ERNERUDH J: Cytokine changes in postmenopausal women treated with estrogens: a placebo-controlled study. Am. J. Reprod. Immunol. (2002) 48:63-69.
115. BROOKS-ASPLUND EM, TUPPER CE, DAUN JM, KENNEY WL, CANNON JG: Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine (2002) 19:193-200.
116. VONGPATANASIN W, TUNCEL M, WANG Z, ARBIQUE D, MEHRAD B, JIALAL I: Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J. Am. Coll. Cardiol. (2003) 41:1358-1363.
117. RIDKER PM, HENNEKENS CH, RIFAI N, BURING JE, MANSON JE: Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation (1999) 100:713-716.
118. DECENSI A, OMODEI U, ROBERTSON C et al.: Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation (2002) 102:1224-1228.
119. MODENA MG, BURSI F, FANTINI G et al.: Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am. J. Med. (2002) 113:331-334.
120. POST MS, VAN DER MOOREN MJ, STEHOUWER CD et al.: Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb. Haemost. (2002) 88:605-610.
121. VEGETO E, BELCREDITO S, ETTERI S et al.: Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. USA (2003) 100:9614-9619.
122. BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. (2000) 6:916-919.
123. WYSS-CORAY T, LOIKE JD, BRIONNE TC et al.: Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat. Med. (2003) 9:453-457.
124. SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature (1999) 400:173-177.
125. NICOLL JA, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-beta peptide: a case report. Nat. Med. (2003) 9:448-452.
126. AISEN PS, DAVIS KL, BERG JD et al.: A randomized controlled trial of prednisone in Alzheimer's disease. Neurology (2000) 54:588-593.
127. AISEN PS, SCHAFER KA, GRUNDMAN M et al.: Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA (2003) 289:2819-2826.
128. SNOWDON DA, GREINER LH, MORTIMER JA, RILEY KP, GREINER PA, MARKESBERY WR: Brain infarction and the clinical expression of Alzheimer's disease. JAMA (1997) 277:813-817.
129. VERMEER SE, PRINS ND, DEN HEIJER T, HOFMAN A, KOUDSTAAL P, BRETELER MM: Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. (2003) 348: 1215-1222.
130. HULETTE C, NOCHLIN D, MCKEEL D et al.: Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology (1997) 48:668-672.
131. ZEKRY D, HAUW JJ, GOLD G: Mixed dementia: epidemiology, diagnosis, and treatment. J. Am. Geriatr. Soc. (2002) 50:1431-1438.
132. JELLINGER KA, ATTEMS J: Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study. Acta Neuropathol. (Berl) (2002) 105:14-17.
133. ZEKRY D, DUYCKAERTS C, MOULIAS R et al.: Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol. (Berl.) (2002) 103:481-487.
134. OTT A, SLOOTER AJC, HOFMAN A et al.: Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam study. Lancet (1998) 351:1840-1843.
135. OTT A, STOLK RP, VAN HARSKAMP F, POLS HA, HOFMAN A, BRETELER MM: Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology (1999) 53:1937-1942.
136. MACKNIGHT C, ROCKWOOD K, AWALT E, MCDOWELL I: Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dementia (2002) 14:77-83.
137. TAN ZS, SESHADRI S, BEISER A et al.: Plasma total cholesterol level as a risk factor for Alzheimer's disease: the Framingham Study. Arch. Intern. Med. (2003) 163:1053-1057.
138. NIWA K, KAZAMA K, YOUNKIN L, YOUNKIN SG, CARLSON GA, IADECOLA C: Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. (2002) 283:H315-H323.
139. OHKURA T, MATSUDA H, IWASAKI N et al.: Effect of estrogen on regional cerebral blood flow in postmenopausal women. J. Jpn Menopause Soc. (1996) 4:254-261.
140. GREENE RA: Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease. Int. J. Fertil. Womens Med. (2000) 45:253-257.
141. RESNICK SM, MAKI PM, GOLSKI S, KRAUT MA, ZONDERMAN AB: Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm. Behav. (1998) 34:171-182.
142. MAKI PM, RESNICK SM: Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol. Aging (2000) 21:373-383.
143. LIEBERMAN EH, GERHARD MD, UEHATA A et al.: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. (1994) 121:936-941.
144. KOH KK,JIN DK, YANG SH et al.: Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation (2001) 103:1961-1966.
145. GUETTA V, QUYYUMI AA, PRASAD A, PANZA JA, WACLAWIW M, CANNON III RO: The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation (1997) 96:2795-2801.
146. CHEN Z, YUHANNA IS, GALCHEVA-GARGOVA Z, KARAS RH, MENDELSOHN ME, SHAUL PW: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. (1999) 103:401-406.
147. HERRINGTON DM, ESPELAND MA, CROUSE JRR et al.: Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1955-1961.
148. KHETAWAT G, FARADAY N, NEALEN ML et al.: Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood (2000) 95:2289-2296.
149. MOR G, SAPI E, ABRAHAMS VM et al.: Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immunol. (2003) 170:114-122.
150. MOLERO L, GARCIA-DURAN M, DIAZ-RECASENS J, RICO L, CASADO S, LOPEZ-FARRE A: Expression of estrogen receptor subtypes and neuronal nitric oxide synthase in neutrophils from women and men: regulation by estrogen. Cardiovasc. Res. (2002) 56:43-51.
151. DE VALK-DE ROO GW, STEHOUWER CD, MEIJER P et al.: Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2993-3000.
152. NOZAKI M, OGATA R, KOERA K, HASHIMOTO K, NAKANO H: Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric (1999) 2:124-130.
153. ACS N, VAJO Z, MIKLOS Z et al.: The effects of postmenopausal hormone replacement therapy on hemostatic variables: a mera-analysis of 46 studies. Gynecol. Endocrinol. (2002) 16:335-346.
154. LOWE GD, UPTON MN, RUMLEY A, MCCONNACHIE A, O'REILLY DS, WATT GC: Different effects of oral and transdermal hormone replacement therapies on Factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey. Thromb. Haemost. (2002) 86:550-556.
155. NORRIS LA, JOYCE M, O'KEEFFE N, SHEPPARD BL, BONNAR J: Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas (2002) 43:125-133.
156. ZEGURA B, KEBER I, SEBESTJEN M, KOENIG W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis (2003) 168:123-129.
157. ROSS R: Mechanisms of disease: atherosclerosis - an inflammatory disease. N. Engl. J. Med. (1999) 340:115-126.
158. CHAN SY, MANCINI GB, KURAMOTO L, SCHULZER M, FROHLICH J, IGNASZEWSKI A: The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J. Am. Coll. Cardiol. (2003) 42:1037-1043.
159. WALSH BW, SCHIFF I, ROSNER B, GREENBERG L, RAVNIKAR V, SACKS FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. (1991) 325:1196-1204.
160. WATANABE T, AKISHITA M, NAKAOKA T et al.: Estrogen receptor beta mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation. Cardiovasc. Res. (2003) 59:734-744.
161. SHAUL PW: Regulation of endothelial nitric oxide synthase: location, location, location. Ann. Rev. Physiol. (2002) 64:749-774.
162. HODIS HN, MACK WJ, LOBO RA et al.: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (2001) 135:939-953.
163. HERRINGTON DM, REBOUSSIN DM, BROSNIHAN KB et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N. Engl. J. Med. (2000) 343:522-529.
164. ANGERER P, STORK S, KOTHNY W, SCHMITT P, VON SCHACKY C: Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler. Thromb. Vasc. Biol. (2001) 21:262-268.
165. HODIS HN, MACK WJ, AZEN SP et al.: Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med. (2003) 349:535-545.
166. MANSON JE, HSIA J, JOHNSON KC et al.: Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. (2003) 349:523-534.
167. HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA (1998) 280:605-613.
168. GRODSTEIN F, MANSON JE, STAMPFER MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann. Intern. Med. (2001) 135:1-8.
169. SIMON JA, HSIA J, CAULEY JA et al.: Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS). Circulation (2001) 103:638-642.
170. VISCOLI CM, BRASS LM, KERNAN WN, SARREL SM, SUISSA S, HORWITZ RI: A clinical trial of estrogen-replacement therapy after ischemic stroke. N. Engl. J. Med. (2001) 345:1243-1249.
171. GRODSTEIN F, MANSON JE, COLDITZ GA, WILLETT WC, SPEIZER FE, STAMPFER MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. (2000) 133:933-941.
172. HONJO H, OGINO Y, TANAKA K et al.: An effect of conjugated estrogen to cognitive impairment in women with senile dementia - Alzheimer's type: a placebo-controlled double blind study. J. Jpn Menopause Soc. (1993) 1:167-171.
173. ASTHANA S, CRAFT S, BAKER LD et al.: Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology (1999) 24:657-677.
174. ASTHANA S, BAKER LD, CRAFT S et al.: High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology (2001) 57:605-612.
175. HENDERSON VW, PAGANINI-HILL A, MILLER BL et al.: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology (2000) 54:295-301.
176. MULNARD RA, COTMAN CW, KAWAS C et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. JAMA (2000) 283:1007-1015.
177. WANG PN, LIAO SQ, LIU RS et al.: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology (2000) 54:2061-2066.
178. THAL LJ, THOMAS RG, MULNARD R, SANO M, GRUNDMAN M, SCHNEIDER L: Estrogen levels do not correlate with improvement in cognition. Arch. Neurol. (2003) 60:209-212.
179. DORAISWAMY PM, BIEBER F, KAISER L, KRISHNAN KR, REUNING-SCHERER J, GULANSKI B: The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology (1997) 48:1511-1517.
180. HENDERSON VW, WATT L, BUCKWALTER JG: Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology (1996) 21:421-430.
181. STURGEON SR, SCHAIRER C, BRINTON LA, PEARSON T, HOOVER RN: Evidence of a healthy estrogen user survivor effect. Epidemiology (1995) 6:227-231.
182. MATTHEWS KA, KULLER LH, WING RR, MEILAHN EN, PLANTINGA P: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am. J. Epidemiol. (1996) 143:971-978.
183. BARTUS RT DEAN RL, BEER B, LIPPA AD: The cholinergic hypothesis of geriatric memory dysfunction. Science (1981) 217:208-217.
184. CONNER JM, CULBERSON A, PACKOWSKI C, CHIBA AA, TUSZYNSKI MH: Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron (2003) 38:819-829.
185. SINGH M, MEYER EM, MILLARD WJ, SIMPKINS JW. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res. (1994) 644:305-312.
186. FADER AJ, HENDRICSON AW, DOHANICH GP: Estrogen improves performance of reinforced T-maze alternation and prevents the amnestic effects ofscopolamine administered systemically or intrahippocampally. Neurobiol. Learn. Mem. (1998) 69:225-240.
187. GIBBS RB: Basal forebrain cholinergic neurons are necessary for estrogen to enhance acquisition of a delayed matching-to-position T-maze task. Horm. Behav. (2002) 42:245-257.
188. DAVIS KL, THAL LJ, GAMZU ER et al.: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. (1992) 327:1253-1259.
189. ROGERS SL, FARLOW MR, DOODY RS, MOHS R, FRIEDHOFF LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 50:136-145.
190. RÖSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J. (1999) 318:633-640.
191. RASKIND MA, PESKIND ER, WESSEL T, YUAN W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology (2000) 54:2261-2268.
192. SCHNEIDER LS, FARLOW MR, HENDERSON VW. POGODA JM: Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology (1996) 46:1580-1584.
193. RIGAUD AS, ANDRE G, VELLAS B, TOUCHON J, PERE JJ: No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology (2003) 60:148-149.
194. MANLY JJ, MERCHANT CA, JACOBS DM et al.: Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology (2000) 54:833-837.
195. HOGERVORST E, SMITH AD: The interaction of serum folate and estradiol levels in Alzheimer's disease. Neuroendocrinol. Lett. (2002) 23:155-160.
196. GEERLINGS MI, LAUNER LJ, DE JONG FH et al.: Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann. Neurol. (2003) 53:607-615.
197. HEYMAN A, WILKINSON WE, STAFFORD JA, HELMS JJ, SIGMON AH, WEINBERG T: Alzheimer's disease: a study of epidemiological aspects. Ann. Neurol. (1984) 15:335-341.
198. AMADUCCI LA, FRATIGLIONI L, ROCCA WA et al.: Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology (1986) 36:922-931.
199. BROE GA, HENDERSON AS, CREASEY H et al.: A case-control study of Alzheimer's disease in Australia. Neurology (1990) 40:1698-1707.
200. GRAVES AB, WHITE E, KOEPSELL TD et al.: A case-control study of Alzheimer's disease. Ann. Neurol. (1990) 28:766-774.
201. BRENNER DE, KUKULL WA, STERGACHIS A et al.: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am. J. Epidemiol. (1994) 140:262-267.
202. MORTEL KF, MEYER JS: Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J. Neuropsychiatry Clin. Neurosci. (1995) 7:334-337.
203. SESHADRI S, ZOMBERG GL, DERBY LE, MYERS MW, JICK H, DRACHMAN DA: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. Arch. Neurol. (2001) 58:435-440.
204. BIRGE SJ: The role of estrogen deficiency in the aging central nervous system. In: Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Lobo RA (Ed.), Raven Press, New York, USA (1994):153-157.
205. HENDERSON VW, PAGANINI-HILL A, EMANUEL CK, DUNN ME, BUCKWALTER JG: Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch. Neurol. (1994) 51:896-900.
206. PAGANINI-HILL A, HENDERSON VW: Estrogen replacement therapy and risk of Alzheimer's disease. Arch. Intern. Med. (1996) 156:2213-2217.
207. TANG M-X, JACOBS D, STERN Y et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 348:429-432.
208. LERNER A, KOSS E, DEBANNE S, ROWLAND D, SMYTH K, FRIEDLAND R: Smoking and oestrogen replacement therapy as protective factors for Alzheimer's disease. Lancet (1997) 349:403-404 (Letter).
209. KAWAS C, RESNICK S, MORRISON A et al.: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology (1997) 48:1517-1521.
210. BALDERESCHI M, DI CARLO A, LEPORE V et al.: Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology (1998) 50:996-1002.
211. WARING SC, ROCCA WA, PETERSEN RC, O'BRIEN PC, TANGALOS EG, KOKMEN E: Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology (1999) 52:965-970.
212. SLOOTER AJ, BRONZOVA J, WITTEMAN JC, VAN BROECKHOVEN C, HOFMAN A, VAN DUIJN CM: Estrogen use and early onset Alzheimer's disease: a population-based study. J. Neurol. Neurosurg. Psychiatry (1999) 67:779-781.
213. ZANDI PP, CARLSON MC, PLASSMAN BL et al.: Hormone replacement therapy and incidence of Alzheimer's disease on older women: the Cache County study. JAMA (2002) 288:2123-2129.
214. YAFFE K, SAWAYA G, LIEBERBURG I, GRADY D: Estrogen therapy in postmenopausal women. JAMA (1998) 279:688-695.
215. HOGERVORST E, WILLIAMS J, BUDGE M, RIEDEL W, JOLLES J: The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience (2000) 101:485-512.
216. LEBLANC ES,JANOWSKY J, CHAN BKS, NELSON HD: Hormone replacement therapy and cognition: systemic review and meta-analysis. JAMA (2001) 285:1489-1499.
217. JOKELA H, DASTIDAR P, RONTU R et al.: Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J. Clin. Endocrinol. Metab. (2003) 88:4348-4354.
218. RICE MM, GRAVES AB, MCCURRY SM et al.: Postmenopausal estrogen and esrrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: the Kame Project. Arch. Intern. Med. (2000) 160:1641-1649.
219. JEZIERSKI MK, SOHRABJI F: Neurotrophin expression in the reproductively senescent forebrain is refractory to estrogen stimulation. Neurobiol. Aging (2001) 22:309-319.
220. SAVONENKO AV, MARKOWSKA, AL: The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Neuroscience (2003) 119:821-830.
221. PHILLIPS SM, SHERWIN BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology (1992) 17:485-495.
222. BINDER EF, SCHECHTMAN KB, BIRGE SJ, WILLIAMS DB, KOHRT WM: Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas (2001) 38:137-146.
223. WOOLLEY CS, GOULD E, FRANKFURT M, MCEWEN BS: Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J. Neurosci. (1990) 10:4035-4039.
224. SILVA I, MELLO LEAM, FREYMÜLLER E, HAIDAR MA, BARACAT EC: Onset of estrogen replacement has a critical effect on synaptic density ofCA1 hippocampus in ovariectomized adult rats. Menopause (2003) 10:406-411.
225. GIBBS RB: Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol. Aging (2000) 21:107-116.
226. HENDERSON VW, DUDLEY EC, GUTHRIE JR, BURGER HG, DENNERSTEIN L: Estrogen exposures and memory at midlife: a population-based study of women. Neurology (2003) 60:1369-1371.
227. MEYER PM, POWELL LH, WILSON RS et al.: A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology (2003) 61:801-806.
228. BRETT KM, CHONG Y: Hormone Replacement Therapy: Knowledge and Use in the United States. National Center for Health Statistics, Hyattsville, MD, USA (2001).
229. ELIAS MF, BEISER A, WOLF PA, AU R, WHITE RF, D'AGOSTINO RB: The preclinical phase of Alzheimer's disease: a 22-year prospective study of the Framingham cohort. Arch. Neurol. (2000) 57:808-813.
230. SMALL BJ, FRATIGLIONI L, VIITANEN M, WINBLAD B, BÄCKMAN L: The course of cognitive impairment in preclinical Alzheimer's disease. Arch. Neurol. (2000) 57:839-844.
231. RESNICK SM, HENDERSON VW: Hormone therapy and risk of Alzheimer's disease: a critical time. JAMA (2002) 288:2170-2172.
232. ETTINGER B, PRESSMAN A, SILVER P: Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause (1999) 6:282-289.
233. COSGRAVE MP, TYRRELL J, MCCARRON M, GILL M, LAWLOR BA: Age at onset of dementia and age of menopause in women with Down's syndrome. J. Intellect. Disabil. Res. (1999) 43:461-465.
234. SCHUPF N, PANG D, PATEL BN et al.: Onset of dementia is associated with age at menopause in women with Down's syndrome. Ann. Neurol. (2003) 54:433-438.
235. HEMMINKI E, MALIN M, TOPO P: Selection to postmenopausal therapy by women's characteristics. J. Clin. Epidemiol. (1993) 46:211-219.
236. DERBY CA, HUME AL, MCPHILLIPS JB, BARBOUR MM, CARLETON RA: Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers. Am. J. Obstet. Gynecol. (1995) 173:544-550.
237. MOORHEAD T, HANNAFORD P, WARSKYJ M: Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br. J. Obstet. Gynaecol. (1997) 104:290-297.
238. WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288:321-333.
239. RAPP SR, ESPELAND MA, SHUMAKER SA et al.: The effect of estrogen with progestin treatment on global cognitive function in postmenopausal women: results from the Women's Health Initiative Memory Study. JAMA (2003) 289:2663-2672.
240. BROWN TJ, SCHERZ B, HOCHBERG RB, MACLUSKY NJ: Regulation of estrogen receptor concentrations in the rat brain: effects of sustained androgen and estrogen exposure. Neuroendocrinology (1996) 63:53-60.
241. SHIMA N, YAMAGUCHI Y, YURI K: Distribution of estrogen receptor beta mRNA-containing cells in ovariectomized and estrogen-treated female rat brain. Anat. Sci. Int. (2003) 78:85-97.
242. PETERSEN RC, DOODY R, KURZ A et al.: Current concepts in mild cognitive impairment. Arch. Neurol. (2001) 58:1985-1992.
243. NILSEN J, BRINTON RD: Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc. Natl. Acad. Sci. USA (2003) 100:10506-10511.